The role of biomarkers in community-acquired pneumonia: Predicting mortality and response to adjunctive therapy

Critical Care

Volumn 12, Issue SUPPL. 6, 2008, Pages

  Mira, Jean Paul ^a   Max, Adeline ^a   Burgel, Pierre Regis ^b  

^a Université Paris Descartes ^*  (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 5; C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 72; HORMONE PRECURSOR; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 6; LYMPHOTOXIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCALCITONIN; PROTEIN C; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; VASOPRESSIN; PHARMACEUTICAL VEHICLES AND ADDITIVES;

BLOOD CLOTTING; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DETERIORATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GENETIC SUSCEPTIBILITY; HOSPITAL PATIENT; HUMAN; MARKER GENE; MEDICAL DECISION MAKING; MORTALITY; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SEPSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; COMMUNICABLE DISEASE; METABOLISM; PNEUMONIA; PREDICTION AND FORECASTING;

ADJUVANTS, PHARMACEUTIC; BIOLOGICAL MARKERS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PNEUMONIA; PREDICTIVE VALUE OF TESTS;

EID: 57049131997     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc7028     Document Type: Review

References (23)

1. Niederman MS McCombs JS Unger AN Kumar A Popovian R The cost of treating community-acquired pneumonia Clin Ther 1998, 20:820-837 10.1016/ S0149-2918(98)80144-6 9737840
2. MacFarlane JT Boldy D 2004 update of BTS pneumonia guidelines: What's new? Thorax 2004, 59:364-366 1747016 15115857 10.1136/thx.2004.024992
3. Restrepo MI Anzueto Z The role of new therapies for severe community-acquired pneumonia Curr Opin Infect Dis 2006, 19:557-564 10.1097/QCO.0b013e3280106b7f 17075331
4. Kaplan V Clermont G Griffin MF Kasal J Watson RS Linde-Zwirble WT Angus DC Pneumonia: Still the old man's friend? Arch Intern Med 2003, 163:317-323 10.1001/archinte.163.3.317 12578512
5. Rello J Demographics, guidelines and clinical experience in severe community-acquired pneumonia Crit Care 2008, 12(Suppl 5):S2 10.1186/ cc7035
6. Mandell LA Wunderlink RG Anzueto A Bartlett JG Campbell D Dean NC Dowell SF File TM Musher DM Niederman MS Torres A Whitney CG Infectious Diseases Society of America/American Thoracic Society consenses guidelines on the management of community-acquired pneumonia in adults Clin Infect Dis 2007, 44:S27-S72 10.1086/511159 17278083
7. Barlow G Nathwani D Davey P The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia Thorax 2007, 62:253-259 10.1136/thx.2006.067371 16928720
8. Man YS Lee N Ip M Antonio GE Chau SS Mak P Graham GA Zhang M Lui G Chan PKS Ahuja AT Hui DS Sung JJ Rainer TH Prospective comparison of three predictive rules for assessing severity of community acquired pneumonia in Hong Kong Thorax 2007, 62:348-353 10.1136/thx.2006.069740 17121867
9. Muller B Harbarth S Stolz D Bingisser R Muller C Leuppi J Nusbaumer C Tamm M Christ-Crain M Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia BMC Infect Dis 2007, 7:10 1821031 17335562 10.1186/1471-2334-7-10
10. Huang D Weissfeld LA Kellum JA Yealy DM Kong L Martino M Angus DC GenIMS Investigators Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia Ann Emerg Med 2008, 52:48-58 10.1016/ j.annemergmed.2008.01.003 18342993
11. Kruger S Papassotiriou J Marre R Richter K Schumann C von Baum H Morgenthaler NG Suttorp N Welte T CAPNETZ Study Group Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community acquired pneumonia: Results from the German competence network CAPNETZ Intensive Care Med 2007, 33:2069-2078 10.1007/ s00134-007-0895-5 17938883
12. Christ-Crain M Morgenthaler NG Stolz D Muller C Bingisser R Harbarth S Tamm M Struck J Bergmann A Muller B Pro-adrenomedullin to predict severity and outcome in community acquired pneumonia Crit Care 2006, 10:R96 1550935 16805922 10.1186/cc4443
13. Yende S Tuomanen EI Wunderink R Kanaya A Newman AB Harris T de Rekeneire N Kritchevsky SB Preinfection systemic inflammatory markers and risk of hospitalization due to pneumonia Am J Resp Crit Care Med 2005, 172:1440-1446 10.1164/rccm.200506-888OC 16166617
14. Kellum J Kong L Fink MP Weissfeld LA Yealy DM Pinsky MR Fine J Krichevsky A Delude RL Angus DC GenIMS investigators Understanding the inflammatory cytokine response in pneumonia and sepsis: Results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) study Arch Intern Med 2007, 167:1655-1663 10.1001/archinte.167.15.1655 17698689
15. Yende S D'Angelo G Kellum JA Weissfeld L Fine J Welch RD Kong L Carter M Angus DC GenIMS Investigators Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis Am J Respir Crit Care Med 2008, 177:1242-1247 10.1164/rccm.200712-1777OC 18369199
16. Querol-Ribelles JM Tenias JM Grau E Querol-Borras JM Climent JL Gomez E Martinez I Plasma d-dimer levels correlate with outcomes in patients with community-acquired pneumonia Chest 2004, 126:1087-1092 10.1378/ chest.126.4.1087 15486368
17. Waterer GW ElBahlawan L Quasney MW Zhang Q Kessler LA Wunderink RG Heat shock protein 70-2+1267 AA homozygotes have an increased risk of septic shock in adults with community-acquired pneumonia Crit Care Med 2003, 31:1367-1372 10.1097/01.CCM.0000063088.86079.03 12771604
18. Wattanathum A Manocha S Groshaus H Russell JA Walley KR Interleukin-10 haplotype associated with increased mortality in critically ill patients with sepsis from pneumonia but not in patients with extrapulmonary sepsis Chest 2005, 128:1690-1698 10.1378/chest.128.3.1690 16162776
19. Yende S Angus DC Ding J Newman AB Kellum JA Li R Ferrell RE Zmuda J Kritchevsky SB Harris TB Garcia M Yaffe K Wunderink RG for the Health ABC Study 4G/5G plasminogen inhibitor-1 polymorphisms and haplotypes are associated with pneumonia Am J Resp Crit Care Med 2007, 176:1129-1137 10.1164/rccm.200605-644OC 17761618
20. Wunderink RG Waterer GW Genetics of community-acquired pneumonia Semin Resp Crit Care Med 2005, 26:553-562 10.1055/s-2005-925522
21. Christ-Crain M Stolz D Bingisser R Muller C Miedinger D Huber PR Zimmerli W Harbarth S Tamm M Muller B Procalcitonin guidance of antibioitic therapy in community-acquired pneumonia: A randomized trial Am J Resp Crit Care Med 2006, 174:84-93 10.1164/rccm.200512-1922OC 16603606
22. Schuetz P Christ-Crain M Wolbers M Schild U Thomann R Falconnier C Widmer I Neidert S Blum CA Schoneberger R Henzen C Bregenzer T Hoess C Krause M Bucher HC Zimmerli W Muller B ProHOSP study group Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: A prospective, multicenter, randomized controlled trial BMC Health Serv Res 2007, 7:102 1947969 17615073 10.1186/1472-6963-7-102
23. Menendez R Cavalcanti M Reyes S Mensa J Martinez R Marcos MA Filella X Niederman M Torres A Markers of the treatment failure in hospitalized community acquired pneumonia Thorax 2008, 63:447 10.1136/thx.2007.086785 18245147